Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13786723 | 0.98 | NAAA (0.52) | TSHRHPGDNAAAHCAR2EPHX1 | |
| SCHEMBL3666982 | 0.98 | NAAA (0.52) | TSHRHPGDNAAAHCAR2EPHX1 | |
| SCHEMBL18864334 | 0.98 | NAAA (0.52) | TSHRHPGDNAAAHCAR2EPHX1 | |
| SCHEMBL10519867 | 0.98 | NAAA (0.52) | TSHRHPGDNAAAHCAR2EPHX1 | |
| SCHEMBL5537440 | 0.94 | TSHR (0.59) | TSHRHPGDNAAAHCAR2EPHX1 | |
| SCHEMBL4123603 | 0.90 | FAAH (0.52) | ATMCYP3A4TP53NPSR1FAAH | |
| SCHEMBL4123609 | 0.90 | FAAH (0.52) | ATMCYP3A4TP53NPSR1FAAH | |
| SCHEMBL4364910 | 0.90 | FAAH (0.52) | ATMCYP3A4TP53NPSR1FAAH | |
| SCHEMBL284885 | 0.89 | TSHR (0.50) | TSHRHPGDNAAAHCAR2EPHX1 | |
| SCHEMBL21985904 | 0.89 | MEN1 (0.44) | TSHRHPGDNAAAHCAR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008013427-A1 | ORGANIC TFTS AND METHOD FOR FABRICATING THE SAME | LG CHEM, LTD. (KR) | 2008-01-31 | — | — | WO | claimed |
| EP-3096369-B1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | LG CHEMICAL LTD (KR) | 2020-10-14 | — | — | EP | disclosed |
| US-20180179499-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | LCY BIOSCIENCES INC. (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-3303375-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BioAmber Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170113993-A1 | ORGANIC ACIDS FROM HOMOCITRATE AND HOMOCITRATE DERIVATIVES | MITSUI & CO., LTD. (JP) | 2017-04-27 | — | — | US | disclosed |
| EP-3155113-A2 | ORGANIC ACIDS FROM HOMOCITRATE AND HOMOCITRATE DERIVATIVES | Bioamber Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2443486-B1 | BIOMEDICAL DEVICES | BAUSCH & LOMB (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2016196962-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BIOAMBER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160343956-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | LG CHEMICAL LTD (KR) | 2016-11-24 | — | — | US | disclosed |
| EP-3096369-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | LG Chem, Ltd. (KR) | 2016-11-23 | — | — | EP | disclosed |
| US-20060084819-A1 | Total synthesis of myriaporones | LOSADA CARLOS D P | 2006-04-20 | — | — | US | disclosed |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2006-01-26 | — | — | US | disclosed |
| CN-1229382-C | Semi-synthetic process and intermediates thereof | PHARMA MAR SA (ES) | 2005-11-30 | — | — | CN | disclosed |
| EP-1287004-B1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCIDIN COMPOUND | PHARMA MAR SA (ES) | 2005-07-27 | — | — | EP | disclosed |
| EP-1280809-B1 | ANTITUMORAL ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2005-07-06 | — | — | EP | disclosed |
| EP-1496060-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| EP-1185536-B1 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR SA (ES) | 2004-11-24 | — | — | EP | disclosed |
| EP-1289999-B1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR SA (ES) | 2004-11-17 | — | — | EP | disclosed |
| CN-1360588-A | Hemisynthetic method and intermediate thereof | PHARMA MAR SA (ES) | 2002-07-24 | — | — | CN | disclosed |
| US-6342349-B1 | A SOLID SUPPORT SUBSTRATE CONTAINING A CLEAVABLE SIGNAL ELEMENT, A SIGNAL RESPONSIVE MOIETY AND A CLEAVABLE SPACER; ANALYTES BIND THE SIGNAL ELEMENT, ANCHORING THE RESPONSIVE MOIETY TO THE ELEMENT SUBSTRATE-ATTACHING END AFTER CLEAVAGE | BURSTEIN TECHNOLOGIES, INC. | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179499-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | COASY, ADSL, ALAD | TSHR 3786/4885HPGD 1155/4885NAAA 32/4885 |
| US-20060084819-A1 | Total synthesis of myriaporones | CBR3, CBR1, SRR | TSHR 1240/4885HPGD 2786/4885NAAA 2995/4885 |
| US-20160343956-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | DSG1, VCL, SUN2 | TSHR 4583/4885HPGD 4376/4885NAAA 4847/4885 |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | ETV1, ETV6, ETF1 | TSHR 2288/4885HPGD 1408/4885NAAA 4035/4885 |
| US-20170113993-A1 | ORGANIC ACIDS FROM HOMOCITRATE AND HOMOCITRATE DERIVATIVES | HOGA1, FABP4, HAGH | TSHR 4663/4885HPGD 311/4885NAAA 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.